Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

  title={Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.},
  author={Keith M. Sullivan and Ellen A. Goldmuntz and Lynette L Keyes-Elstein and Peter A. Mcsweeney and Ashley Pinckney and Beverly Welch and Maureen D. Mayes and Richard A. Nash and Leslie J. Crofford and Barry Eggleston and Sharon Castina and Linda M. Griffith and Julia S. Goldstein and Dennis Wallace and Oana I. Craciunescu and Dinesh Khanna and R. J. Folz and Jonathan G. Goldin and Eugene William St. Clair and James R. Seibold and Kristine Phillips and Shin Mineishi and Robert W. Simms and Karen Kuhn Ballen and Mark H. Wener and George E Georges and Shelly Heimfeld and Chitra M Hosing and Stephen J. Forman and Suzanne Kafaja and Richard M. Silver and Leroy Griffing and Jan Storek and Sharon A Leclercq and Richard D. Brasington and Mary Ellen Csuka and Christopher N. Bredeson and Carolyn A. Keever-Taylor and Robyn T. Domsic and M. Bashar Kahaleh and Thomas A Jr Medsger and Daniel e. Furst},
  journal={The New England journal of medicine},
  volume={378 1},
BACKGROUND Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma) often has a devastating outcome. We compared myeloablative CD34+ selected autologous hematopoietic stem-cell transplantation with immunosuppression by means of 12 monthly infusions of cyclophosphamide in patients with scleroderma. METHODS We randomly assigned adults (18 to 69 years of age) with severe scleroderma to undergo myeloablative autologous stem-cell transplantation (36 participants) or to receive… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 64 times. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 11 extracted citations


Publications referenced by this paper.
Showing 1-10 of 42 references

Safety and efficacy of subcutaneous tocilizumab in adults with systemic scleThe New England Journal of Medicine Downloaded from at WASHINGTON

D Khanna, CP Denton, A Jahreis
UNIV SCH MED MEDICAL LIB on January • 2018

Manufacture of Autologous CD34+ Selected Grafts in the NIAID-Sponsored HALT-MS and SCOT Multicenter Clinical Trials for Autoimmune Diseases.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation • 2017
View 1 Excerpt

Similar Papers

Loading similar papers…